TY - JOUR T1 - Efficacy of Adjuvant Chemotherapy According to the Pathological Response to Neoadjuvant Chemotherapy Among Patients With Pancreatic Ductal Adenocarcinoma JF - Anticancer Research JO - Anticancer Res SP - 1629 LP - 1639 DO - 10.21873/anticanres.14925 VL - 41 IS - 3 AU - SHOZO MORI AU - TAKU AOKI AU - YUHKI SAKURAOKA AU - TAKAYUKI SHIMIZU AU - TAKAMUNE YAMAGUCHI AU - KYUNG-HWA PARK AU - TAKATSUGU MATSUMOTO AU - TAKAYUKI SHIRAKI AU - YUKIHIRO ISO AU - KEIICHI KUBOTA Y1 - 2021/03/01 UR - http://ar.iiarjournals.org/content/41/3/1629.abstract N2 - Background/Aim: An association between the pathological response to neoadjuvant chemotherapy (NAC) and the efficacy of adjuvant chemotherapy (AC) in patients with pancreatic ductal adenocarcinoma (PDAC) remains unknown. Patients and Methods: A total of 121 patients with PDAC who underwent a pancreatectomy between January 2013 and March 2020 were divided into two groups: an upfront surgery (UFS) group (n=42), and an NAC (gemcitabine plus S-1) group (n=79). In the NAC group, the pathological response was evaluated using the Evans classification. Results: The overall survival was significantly higher in patients with an AC relative dose intensity (RDI) ≥80% than in patients with an AC RDI <80% in the UFS, NAC-Evans IIa, and NAC-Evans IIb+III groups. However, this difference was not observed in the NAC-Evans I group. Conclusion: AC is preferable for patients with NAC-Evans IIa or IIb+III, but more effective AC regimens may be needed for NAC-Evans I patients. ER -